RecruitingNCT07368647

Chronic Radiation Cystitis and Effect of Hyperbaric Oxygen Therapy on Patient Reported Outcomes and Urine Inflammatory Biomarkers


Sponsor

Rachel A. Moses

Enrollment

100 participants

Start Date

Apr 4, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Collection of urine, blood, and tissue samples from patients undergoing hyperbaric oxygen therapy


Eligibility

Min Age: 18 Years

Inclusion Criteria11

  • Cohort 1
  • At least 18 years of age
  • Post pelvic radiation carrying the diagnosis of moderate to severe radiation cystitis and recurrent macroscopic hematuria in the absence of infection or urothelial malignancy. The diagnosis of moderate to severe (Radiation Therapy Oncology Group (RTOG) grade 2, 3-4) RC will be made by board-certified, reconstructive Urologists routinely managing radiation cystitis patients in their practices (RM /WB,III) or co-investigator (JB) using Appendix B and confirmed with cystoscopy and negative urine cytology and/or bladder biopsy to rule out malignancy (which is standard of care of work up of hematuria as defined by the American Urology Association)45 once all other pathologies for gross hematuria have been excluded (including infection, malignancy, etc).
  • Scheduled to, or currently undergoing (initiated within the past 7 days), HBOT as part of standard of care therapy for radiation cystitis Cohort 2 HBOT controls
  • At least 18 years of age
  • Without a history of prior pelvic radiation
  • Scheduled to, or currently undergoing (initiated within the past 7 days) HBOT as part of standard of care therapy for reasons that do not include bladder inflammation) Cohort 3 Healthy controls
  • At least 18 years of age
  • Without history of pelvic radiation or HBOT Cohort 4
  • At least 18 years of age
  • Same as Cohort 1 except they OPT-OUT of participation in HBO therapy.

Exclusion Criteria6

  • All Cohorts
  • Pregnant or lactating (females will be asked if there is any chance they could be pregnant).
  • Uncompensated heart failure, uncompensated fluid overload, or uncompensated myocardial infarction preventing therapeutic HBOT
  • A history of: uncontrolled seizure disorder, active urinary tract infection, active Grave's disease, cystic fibrosis, sickle cell anemia, known HIV, or any autoimmune disease not in remission that requires active systemic steroid therapy or immune modulating medications.
  • Refusal to sign IRB approved informed consent document
  • Prior participation in a clinical trial that could potentially affect immunological status

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERHyperbaric Oxygen Therapy

Hyperbaric Oxygen Therapy (HBOT) is the only non-invasive treatment modality for Radiation Cystitis, performed by placing patients in chambers and introducing them to steep oxygen gradients (100% oxygen at a pressure of 240-250kPa) for 80 to 90 minutes per day in up to 60 consecutive sessions.


Locations(1)

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07368647


Related Trials